-
B305226-50mgdBET1 is a hybrid molecule that combines (+)-JQ1 and thalidomide. It induces cereblon-dependent BET protein degradation in vitro (EC50: 430 nM) and induces apoptosis.
-
B305226-5mgdBET1 is a hybrid molecule that combines (+)-JQ1 and thalidomide. It induces cereblon-dependent BET protein degradation in vitro (EC50: 430 nM) and induces apoptosis.
-
D422195-1mldBET1 is a hybrid molecule that combines (+)-JQ1 and thalidomide. It induces cereblon-dependent BET protein degradation in vitro (EC50: 430 nM) and induces apoptosis.
-
D649097-10mgDBM-MMAF is a agent-linker conjugate composed of a potent antitubulin agent MMAF and a linker DBM to make antibody agent conjugate (ADC)Form:SolidIC50&: Target:Auristatin.
-
D649097-5mgDBM-MMAF is a agent-linker conjugate composed of a potent antitubulin agent MMAF and a linker DBM to make antibody agent conjugate (ADC)Form:SolidIC50&: Target:Auristatin.
-
D650173-10mgDC0-NH2 is an effector moiety for ADC and a simplified analog of DC1 with better stability. DC0-NH2 is about 1000-fold more cytotoxic than commonly used anticancer agents (ex. Doxorubicin). DC0-NH2 can bind to the minor groove of DNA, followed by
-
D650173-1mgDC0-NH2 is an effector moiety for ADC and a simplified analog of DC1 with better stability. DC0-NH2 is about 1000-fold more cytotoxic than commonly used anticancer agents (ex. Doxorubicin). DC0-NH2 can bind to the minor groove of DNA, followed by
-
D650173-5mgDC0-NH2 is an effector moiety for ADC and a simplified analog of DC1 with better stability. DC0-NH2 is about 1000-fold more cytotoxic than commonly used anticancer agents (ex. Doxorubicin). DC0-NH2 can bind to the minor groove of DNA, followed by
-
D656161-1mlDC0-NH2 is an effector moiety for ADC and a simplified analog of DC1 with better stability. DC0-NH2 is about 1000-fold more cytotoxic than commonly used anticancer agents (ex. Doxorubicin). DC0-NH2 can bind to the minor groove of DNA, followed by
-
D650937-5mgDC1Sme, a DC1 derivative, exhibits IC 50 values of 22 pM, 10 pM, 32 pM and 250 pM for Ramos, Namalwa, HL60/s and COLO 205 cancer cells, respectively. DC1, an analogue of the minor groove-binding DNA alkylator CC-1065, is a ADC Cytotoxin . DC1 can be
-
D646872-10mgDeruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and amaleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.In VitroAntibody-drug conjugates deliver anticancer agents selectively and efficiently
-
D646872-50mgDeruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and amaleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.In VitroAntibody-drug conjugates deliver anticancer agents selectively and efficiently